+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening and optimization of ligand conjugates for lysosomal targeting



Screening and optimization of ligand conjugates for lysosomal targeting



Bioconjugate Chemistry 22(11): 2271-2282



The use of lysosome-targeted liposomes may significantly improve the delivery of therapeutic enzymes and chaperones into lysosomes for the treatment of lysosomal storage disorders. The aim of this research was to synthesize new potentially lysosomotropic ligands on a base of Neutral Red and rhodamine B and to study their ability to enhance specific lysosomal delivery of surface-modified liposomes loaded with a model compound, fluorescein isothiocyanate-dextran (FD). The delivery of these liposomes and their content to lysosomes in HeLa cells was investigated by confocal immunofluorescent microscopy, subcellular fractionation, and flow cytometry. Confocal microscopy demonstrated that liposomes modified with derivatives of rhodamine B provide a good rate of colocalization with the specific lysosomal markers. The comparison of fluorescence of FD in lysosomes isolated by subcellular fractionation also showed that the efficiency of lysosomal delivery of the liposomal load by liposomes modified with some of synthesized ligands was significantly higher compared to that with plain liposomes. These results were additionally confirmed by flow cytometry of the intact cells treated with liposomes loaded with 5-dodecanoylaminofluorescein di-β-d-galactopyranoside, a specific substrate for the intralysosomal β-galactosidase, using a number of cell lines, including macrophages with induced phenotype of lysosomal enzyme deficiency; two of the synthesized ligands-rhodamine B DSPE-PEG(2k)-amide and 6-(3-(DSPE-PEG(2k))-thioureido) rhodamine B-demonstrated enhanced lysosomal delivery, in some cases, higher than that for commercially available rhodamine B octadecyl ester, with the best results (the enhancement of the lysosomal delivery up to 75% greater in comparison to plain liposomes) shown for the cells with induced lysosomal enzyme deficiency phenotype. Use of liposomes modified with rhodamine B derivatives may be advantageous for the development of drug delivery systems for the treatment of lysosome-associated disorders.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670288

Download citation: RISBibTeXText

PMID: 21913714

DOI: 10.1021/bc200336j


Related references

Targeting and lysosomal handling of polymethacrylamide oligopeptide conjugates. Gregoriadis, G , Et Al (Ed ) Nato Asi (Advanced Science Institutes) Series Series A Life Sciences, Vol 82 Receptor-Mediated Targeting Of Drugs; 2nd Meeting, Cape Sounion, Greece, June 20-July 1, 1983 X+491p Plenum Press: New York, N Y , Usa; London, England Illus 417-426, 1984, 1985

Immunotoxins, ligand-toxin conjugates and molecular targeting. Pharmacological Research 21 Suppl 2: 35-46, 1989

Targeting tumors using estrogen receptor ligand conjugates. Current Cancer Drug Targets 9(3): 370-380, 2009

Targeting of a lysosomal membrane protein: a tyrosine-containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is necessary and sufficient for targeting to lysosomes. Embo Journal 9(11): 3497-3506, 1990

Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Molecular Pharmacology 57(6): 1104-1113, 2000

Targeting of daunorubicin by covalent and reversible linkage to carrier proteins lysosomal hydrolysis and anti tumoral activity of conjugates prepared with peptidic spacer arms. Drugs under Experimental & Clinical Research 9(4): 303-312, 1983

Optimization of a novel peptide ligand targeting human carbonic anhydrase IX. Plos One 7(5): E38279-E38279, 2012

Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. European Journal of Cancer 40(1): 148-157, 2003

Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Molecular Medicine 15(1-2): 11-20, 2008

Quantitative control of active targeting of nanocarriers to tumor cells through optimization of folate ligand density. Biomaterials 35(27): 8015-8027, 2015

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. Mabs 7(1): 42-52, 2015

Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 116(2): 255-266, 2005

Low molecular weight proteins as carriers for renal drug targeting preparation of drug protein conjugates and drug spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. Journal of Medicinal Chemistry 35(7): 1246-1259, 1992

Quantitative analysis of ligand-EGFR interactions: a platform for screening targeting molecules. Plos One 10(2): E0116610-E0116610, 2016